Citadel Advisors
RCKT icon

Citadel Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Citadel Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$232K Buy
+64,900
New +$258K ﹤0.01% 11092
2025
Q4 		– Sell
-95,200
Closed -$310K – 13829
2025
Q3 		$310K Buy
95,200
+36,900
+63% +$116K ﹤0.01% 10288
2025
Q2 		$143K Buy
58,300
+3,200
+6% +$16.2K ﹤0.01% 11002
2025
Q1 		$368K Buy
55,100
+27,300
+98% +$270K ﹤0.01% 9136
2024
Q4 		$349K Buy
27,800
+4,800
+21% +$72.3K ﹤0.01% 9341
2024
Q3 		$425K Buy
23,000
+2,700
+13% +$55.3K ﹤0.01% 8608
2024
Q2 		$437K Sell
20,300
-27,000
-57% -$620K ﹤0.01% 8326
2024
Q1 		$1.27M Buy
47,300
+17,900
+61% +$508K ﹤0.01% 6437
2023
Q4 		$881K Sell
29,400
-60,700
-67% -$1.34M ﹤0.01% 6917
2023
Q3 		$1.85M Buy
90,100
+65,300
+263% +$1.19M ﹤0.01% 5364
2023
Q2 		$493K Buy
24,800
+9,400
+61% +$190K ﹤0.01% 7969
2023
Q1 		$264K Sell
15,400
-14,200
-48% -$278K ﹤0.01% 9643
2022
Q4 		$579K Sell
29,600
-27,000
-48% -$497K ﹤0.01% 7935
2022
Q3 		$903K Buy
56,600
+37,800
+201% +$590K ﹤0.01% 7213
2022
Q2 		$259K Buy
+18,800
New +$224K ﹤0.01% 10145
2021
Q4 		– Sell
-19,400
Closed -$580K – 14573
2021
Q3 		$580K Sell
19,400
-5,700
-23% -$207K ﹤0.01% 9514
2021
Q2 		$1.11M Buy
25,100
+4,600
+22% +$200K ﹤0.01% 8091
2021
Q1 		$910K Sell
20,500
-300
-1% -$16.5K ﹤0.01% 8352
2020
Q4 		$1.14M Buy
+20,800
New +$758K ﹤0.01% 6528
2020
Q3 		– Sell
-10,300
Closed -$216K – 10622
2020
Q2 		$216K Sell
10,300
-6,000
-37% -$108K ﹤0.01% 8415
2020
Q1 		$227K Buy
16,300
+900
+6% +$17.8K ﹤0.01% 7803
2019
Q4 		$351K Buy
15,400
+3,200
+26% +$53.4K ﹤0.01% 7342
2019
Q3 		$142K Buy
12,200
+900
+8% +$11.2K ﹤0.01% 8326
2019
Q2 		$170K Buy
11,300
+1,000
+10% +$17.5K ﹤0.01% 8289
2019
Q1 		$181K Sell
10,300
-2,800
-21% -$44.2K ﹤0.01% 8275
2018
Q4 		$194K Buy
+13,100
New +$217K ﹤0.01% 7891
2017
Q3 		– Sell
-5,275
Closed -$40K – 7941
2017
Q2 		$40K Sell
5,275
-3,375
-39% -$25.2K ﹤0.01% 7148
2017
Q1 		$69K Buy
8,650
+4,050
+88% +$27.2K ﹤0.01% 6971
2016
Q4 		$112K Buy
+4,600
New +$131K ﹤0.01% 6629

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's RCKT Position: Q1 2026 in Review

Citadel Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q1 2026, closing a stake of 1,299,991 shares — an estimated $5.17M sold.

Citadel Advisors first reported a position in RCKT in Q3 2015 and held it in 39 quarters. The position peaked at $73.7M in Q4 2023. 198 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Citadel Advisors reported no remaining Rocket Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 1,299,991 Rocket Pharmaceuticals shares in Q1 2026, an estimated $5.17M.
  • Citadel Advisors first reported a position in Rocket Pharmaceuticals in Q3 2015 and held it in 39 quarters.
  • Citadel Advisors's Rocket Pharmaceuticals position peaked at $73.7M in Q4 2023.
  • 198 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.